PubRank

A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

Clinical Trial ID NCT01725256

PubWeight™ 0.91‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01725256

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002 31.79
2 Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 12.05
3 Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003 8.95
4 ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009 7.94
5 Treatment of pulmonary arterial hypertension. N Engl J Med 2004 6.88
6 Pulmonary arterial hypertension. N Engl J Med 2004 6.69
7 Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009 6.64
8 Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004 5.79
9 Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 5.31
10 Primary pulmonary hypertension. N Engl J Med 1997 4.97
11 Pulmonary complications of sickle cell disease. N Engl J Med 2008 4.11
12 Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009 3.75
13 Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995 3.70
14 Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009 3.69
15 Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011 3.37
16 Dietary nitrate supplementation reduces the O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. J Appl Physiol (1985) 2009 3.09
17 Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003 2.85
18 Dietary inorganic nitrate improves mitochondrial efficiency in humans. Cell Metab 2011 2.61
19 Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA 2005 2.47
20 Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation 2007 2.46
21 Effects of dietary nitrate on oxygen cost during exercise. Acta Physiol (Oxf) 2007 2.20
22 Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol 2006 2.17
23 Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994 2.14
24 Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med 2004 2.09
25 Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2007 2.03
26 Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 1.91
27 Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006 1.87
28 Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 1.73
29 Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 2009 1.55
30 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2007 1.51
31 Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995 1.51
32 Acute dietary nitrate supplementation improves cycling time trial performance. Med Sci Sports Exerc 2011 1.47
33 Dietary nitrate reduces maximal oxygen consumption while maintaining work performance in maximal exercise. Free Radic Biol Med 2009 1.46
34 HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000 1.45
35 The role of nitric oxide in the pathophysiology of intimal hyperplasia. J Vasc Surg 2007 1.35
36 HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997 1.35
37 Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) 2006 1.31
38 Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats. J Clin Invest 2011 1.30
39 Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996 1.24
40 Dietary nitrate reduces muscle metabolic perturbation and improves exercise tolerance in hypoxia. J Physiol 2011 1.23
41 Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One 2011 1.19
42 Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003 1.15
43 Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006 1.11
44 Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996 1.09
45 Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 1.08
46 Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006 1.08
47 Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005 1.07
48 Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic Biol Med 2010 1.06
49 Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovasc Res 2010 1.05
50 Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10. Cell Biochem Biophys 2011 0.94
51 Inorganic nitrite supplementation for healthy arterial aging. J Appl Physiol (1985) 2014 0.91
52 Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000 0.91
53 Systemic sclerosis-associated myopathy. Ann N Y Acad Sci 2007 0.86
54 Mitochondria as metabolizers and targets of nitrite. Nitric Oxide 2009 0.85
55 Severe pulmonary hypertension in COPD: is it a distinct disease? Chest 2005 0.83
56 Nitric oxide gas decreases endothelin-1 mRNA in cultured pulmonary artery endothelial cells. Nitric Oxide 2002 0.80
57 Kinetics of skeletal muscle O2 delivery and utilization at the onset of heavy-intensity exercise in pulmonary arterial hypertension. Eur J Appl Physiol 2011 0.79
58 Validation of Fick cardiac output calculated with assumed oxygen consumption: a study of cardiac output during epoprostenol. Neth Heart J 2004 0.79
59 Protective effect of a selective endothelin a receptor antagonist (BSF 208075) on graft pancreatitis in pig pancreas transplantation. Transplant Proc 2001 0.75
Next 100